NO923542L - Idiotypisk vaksinasjon mot b-cellelymfom - Google Patents

Idiotypisk vaksinasjon mot b-cellelymfom

Info

Publication number
NO923542L
NO923542L NO92923542A NO923542A NO923542L NO 923542 L NO923542 L NO 923542L NO 92923542 A NO92923542 A NO 92923542A NO 923542 A NO923542 A NO 923542A NO 923542 L NO923542 L NO 923542L
Authority
NO
Norway
Prior art keywords
dendritic cells
idiotype
pulsed
cells
cell lymphoma
Prior art date
Application number
NO92923542A
Other languages
English (en)
Other versions
NO923542D0 (no
NO308509B1 (no
Inventor
Heribert Bohlen
Jacques Urbain
Benjamin Van Camp
Kristiaan Thielemans
Original Assignee
Immune Response Corp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23960532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO923542(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immune Response Corp Inc filed Critical Immune Response Corp Inc
Publication of NO923542D0 publication Critical patent/NO923542D0/no
Publication of NO923542L publication Critical patent/NO923542L/no
Publication of NO308509B1 publication Critical patent/NO308509B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
NO923542A 1990-03-14 1992-09-11 FremgangsmÕte for fremstilling av et injiserbart medikament for induksjon av en effektiv immunrespons hos et pattedyr mot patogene lymfocytter som uttrykker et idotypeprotein pÕ cellemembranen samt fremgangsmÕte for fremstilling av idiotypepulse NO308509B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/493,511 US20030072751A1 (en) 1990-03-14 1990-03-14 Idiotypic vaccination against b cell lymphoma
PCT/US1991/001683 WO1991013632A1 (en) 1990-03-14 1991-03-13 Idiotypic vaccination against b cell lymphoma

Publications (3)

Publication Number Publication Date
NO923542D0 NO923542D0 (no) 1992-09-11
NO923542L true NO923542L (no) 1992-09-11
NO308509B1 NO308509B1 (no) 2000-09-25

Family

ID=23960532

Family Applications (1)

Application Number Title Priority Date Filing Date
NO923542A NO308509B1 (no) 1990-03-14 1992-09-11 FremgangsmÕte for fremstilling av et injiserbart medikament for induksjon av en effektiv immunrespons hos et pattedyr mot patogene lymfocytter som uttrykker et idotypeprotein pÕ cellemembranen samt fremgangsmÕte for fremstilling av idiotypepulse

Country Status (12)

Country Link
US (1) US20030072751A1 (no)
EP (1) EP0521897B1 (no)
JP (1) JP2735947B2 (no)
AT (1) ATE124265T1 (no)
AU (1) AU645552B2 (no)
CA (1) CA2078235C (no)
DE (1) DE69110877T2 (no)
DK (1) DK0521897T3 (no)
ES (1) ES2074268T3 (no)
FI (1) FI105452B (no)
NO (1) NO308509B1 (no)
WO (1) WO1991013632A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004807A (en) * 1992-03-30 1999-12-21 Schering Corporation In vitro generation of human dendritic cells
CA2133409C (en) * 1992-04-01 2011-05-24 Ralph M. Steinman Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
AU687733B2 (en) * 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
EP1421947A1 (en) * 1992-07-22 2004-05-26 The Trustees Of Princeton University p53 vaccine
DE69331703D1 (de) * 1992-08-21 2002-04-18 Us Gov Health & Human Serv B-lymphomazellinie und antigen
US5651993A (en) 1992-11-18 1997-07-29 Yale University Specific immune system modulation
CA2158281A1 (en) * 1993-03-15 1994-09-29 Jay A. Berzofsky Peptide coated dendritic cells as immunogens
WO1995034638A1 (en) * 1994-06-14 1995-12-21 The Board Of Trustees Of Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US6340981B1 (en) 1997-06-30 2002-01-22 Sun Microsystems, Inc. Method and apparatus for stroke substitution
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
WO1997022349A1 (en) * 1995-12-20 1997-06-26 The Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US5776746A (en) 1996-05-01 1998-07-07 Genitope Corporation Gene amplification methods
ATE428769T1 (de) 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
CA2321093A1 (en) 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
US8313945B2 (en) 1999-04-20 2012-11-20 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
CA2368855C (en) 1999-04-20 2012-05-29 Richard Leslie Edelson Differentiation of monocytes into functional dendritic cells
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
AT409086B (de) * 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie Neue verwendung von antikörpern als impfstoffe
US8524495B2 (en) 2007-05-16 2013-09-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells

Also Published As

Publication number Publication date
JPH05507905A (ja) 1993-11-11
CA2078235A1 (en) 1991-09-15
EP0521897B1 (en) 1995-06-28
AU7488691A (en) 1991-10-10
ES2074268T3 (es) 1995-09-01
FI924082A (fi) 1992-09-11
DE69110877D1 (de) 1995-08-03
EP0521897A1 (en) 1993-01-13
CA2078235C (en) 2004-01-20
JP2735947B2 (ja) 1998-04-02
FI924082A0 (fi) 1992-09-11
US20030072751A1 (en) 2003-04-17
NO923542D0 (no) 1992-09-11
AU645552B2 (en) 1994-01-20
DE69110877T2 (de) 1995-11-16
ATE124265T1 (de) 1995-07-15
NO308509B1 (no) 2000-09-25
WO1991013632A1 (en) 1991-09-19
FI105452B (fi) 2000-08-31
DK0521897T3 (da) 1995-11-13

Similar Documents

Publication Publication Date Title
NO923542L (no) Idiotypisk vaksinasjon mot b-cellelymfom
DK0669836T3 (da) Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
DK1005870T3 (da) Terapeutisk anvendelse af kimæriske antistoffer mod humant B-lymfocytdifferentieringsantigen til behandling af B-cellelymfom
IT1248760B (it) Dispositivo di iniezione del combustibile per motori e endotermici
NO943920L (no) Vaksineadjuvans
DE69418699D1 (de) Induktion der antworten zytotoxischer t-lymphozyten
DK0504177T3 (da) IL-11, et pattedyrcytokin
FR2620941B1 (fr) Vaccin contenant des adjuvants et des antigenes tumoraux
ATE155813T1 (de) Her2 extrazellulare domäne
ES8608883A1 (es) Procedimiento de preparacion de un conjugado de muramilpeptido y de un hapteno o fragmento haptenico de bajo peso molecular.
MY135673A (en) Monoclonal antibodies for inducing tolerance
Davies et al. Protection of Mice Against Syngeneic Lymphomata
KR890700659A (ko) 항원-특이적 t세포주의 생성방법 및 이의 치료적 용도
IT8050422A0 (it) Dispositivo per la riduzione delle vibrazioni di motori in particolare di motori endotermici ad iniezione
DE68918127D1 (de) Peptidbehandlung von hartnäckigen Infektionskrankheiten.
DE69123252D1 (de) Kreuzreaktive immunisierung gegen influenza
DE69322960D1 (de) Empfängnisverhütender impfstoff
Baenkler Autoimmunity in infectious diseases.
IT212440Z2 (it) Dispositivo riscaldatore di combustibile per motori diesel
NO930820L (no) Patogen-spesifikk ctl terapi
IT1229943B (it) Procedimento e dispositivo di misura dell'anticipo di inizio mandata dell'iniezione, particolarmente in motori diesel
NO872633L (no) Monoklonalt antistoff mot humant plasminogen, samt fremstilling derav.
SE8702038D0 (sv) Sett och anordning for att alstra seismiska pulser
SU681928A1 (ru) Адъювант
IT1181513B (it) Sistema di fissaggio dell'imbottitura sui fianchi di una poltrona

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees